Phibro Animal Health's acquisition of Zoetis' medicated feed additive business has driven significant momentum and improved financial performance. Organic growth and margin expansion is seen across all segments, not just from the Zoetis deal, signaling a real operational turnaround. Despite a 50% share price rally, the stock remains attractively valued at a low double-digit earnings multiple, with manageable leverage.
Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
![]() ZOE 2 months ago | Other | €0.43 Per Share |
![]() ZOE 5 months ago | Other | €0.43 Per Share |
![]() ZOE 7 months ago | Other | €0.37 Per Share |
![]() ZOE 11 months ago | Other | €0.37 Per Share |
![]() ZOE 18 Apr 2024 | Other | €0.37 Per Share |
4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | 1.34 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
11 Feb 2025 Date | | - Cons. EPS | 1.21 EPS |
4 Nov 2024 Date | | - Cons. EPS | - EPS |
![]() ZOE 2 months ago | Other | €0.43 Per Share |
![]() ZOE 5 months ago | Other | €0.43 Per Share |
![]() ZOE 7 months ago | Other | €0.37 Per Share |
![]() ZOE 11 months ago | Other | €0.37 Per Share |
![]() ZOE 18 Apr 2024 | Other | €0.37 Per Share |
4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | 1.34 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
11 Feb 2025 Date | | - Cons. EPS | 1.21 EPS |
4 Nov 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Ms. Kristin C. Peck CEO | XETRA Exchange | US98978V1035 ISIN |
US Country | 13,800 Employees | 18 Jul 2025 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |